| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,697 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sharp Shalini |
CFO |
• – – |
2011-07-26 |
4 |
A |
$0.79 |
$2,963 |
D/D |
3,750 |
301,079 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2011-07-26 |
4 |
A |
$0.79 |
$1,975 |
D/D |
2,500 |
101,661 |
|
- |
|
| Valentine Karen |
VP General Counsel |
• – – |
2011-07-26 |
4 |
A |
$0.79 |
$1,975 |
D/D |
2,500 |
92,568 |
|
- |
|
| Rothwell Timothy G |
Director |
– • – |
2011-07-01 |
4 |
A |
$0.90 |
$9,244 |
D/D |
10,306 |
29,734 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-07-01 |
4 |
A |
$0.83 |
$13,199 |
D/D |
15,834 |
3,001,516 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-06-01 |
4 |
A |
$0.94 |
$13,199 |
D/D |
14,114 |
2,985,682 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2011-05-02 |
4 |
A |
$0.93 |
$13,200 |
D/D |
14,224 |
2,971,568 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2011-04-26 |
4 |
A |
$0.92 |
$3,834 |
D/D |
4,167 |
199,550 |
|
- |
|
| Valentine Karen |
VP, General Counsel |
• – – |
2011-04-26 |
4 |
A |
$0.92 |
$2,300 |
D/D |
2,500 |
90,068 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-04-26 |
4 |
A |
$0.92 |
$3,450 |
D/D |
3,750 |
297,329 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-04-26 |
4 |
A |
$0.92 |
$7,666 |
D/D |
8,333 |
2,957,344 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2011-04-26 |
4 |
A |
$0.92 |
$2,300 |
D/D |
2,500 |
99,161 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-04-01 |
4 |
A |
$0.91 |
$319,033 |
D/D |
350,280 |
2,949,011 |
|
- |
|
| Rothwell Timothy G |
Director |
– • – |
2011-04-01 |
4 |
A |
$0.95 |
$9,246 |
D/D |
9,712 |
19,428 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2011-03-09 |
4 |
A |
$0.98 |
$17,868 |
D/D |
18,233 |
195,383 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2011-03-09 |
4 |
A |
$0.98 |
$5,880 |
D/D |
6,000 |
96,661 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2011-03-09 |
4 |
A |
$0.98 |
$8,538 |
D/D |
8,712 |
87,568 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-03-09 |
4 |
A |
$0.98 |
$14,294 |
D/D |
14,586 |
293,579 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-03-09 |
4 |
A |
$0.98 |
$39,415 |
D/D |
40,219 |
2,598,731 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-03-01 |
4 |
A |
$0.93 |
$13,200 |
D/D |
14,122 |
2,558,512 |
|
- |
|
| Rothwell Timothy G |
Director |
– • – |
2011-02-04 |
4 |
A |
$0.95 |
$9,250 |
D/D |
9,716 |
9,716 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-02-01 |
4 |
A |
$1.00 |
$13,259 |
D/D |
13,259 |
2,544,390 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2011-01-26 |
4 |
A |
$0.95 |
$3,959 |
D/D |
4,167 |
177,150 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2011-01-26 |
4 |
A |
$0.95 |
$2,375 |
D/D |
2,500 |
78,856 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-01-26 |
4 |
A |
$0.95 |
$3,563 |
D/D |
3,750 |
278,993 |
|
- |
|
536 Records found
|
|
Page 14 of 22 |
|
|
